Januvia (sitagliptin) / Ono Pharmaceutical, Merck (MSD) - LARVOL DELTA

Comparative Incidence of Bullous Pemphigoid in Patients Treated with DPP-4 Inhibitors Versus Metformin: A Retrospective Cohort Study (AAD 2026) - "Patients with BP diagnoses following treatment with metformin or a DPP-4 inhibitor (alogliptin, saxagliptin, sitagliptin, linagliptin) were identified using ICD-10 and CPT codes. In this large cohort, DPP-4 inhibitors were associated with greater BP risk compared with metformin, with linagliptin showing the strongest effect. Clinicians should maintain awareness of this potential adverse outcome and consider closer dermatologic monitoring or alternative therapies in high-risk patients. Further investigation is warranted to clarify mechanisms and inform safer prescribing practices."

Retrospective data • Bullous Pemphigoid • Dermatology • Dermatopathology • Diabetes • Immunology • Metabolic Disorders • Type 2 Diabetes Mellitus

Henoch-Schönlein purpura induced by sitagliptin: a case report (AAD 2026) - "The patient was then treated with celecoxib, colchicine, and cefadroxil for wound infection. To our knowledge, this is the first case of sitagliptin-induced HSP and the third case of sitagliptin-induced LCV documented in the literature.3,4 Overall, this case highlights a new potential association of DPP-4 inhibitors with HSP, which may have systemic consequences."

Case report • Clinical • Diabetes • Infectious Disease • Metabolic Disorders • Respiratory Diseases • Type 2 Diabetes Mellitus • Vasculitis

Integrative Pharmacological and Computational Analysis of Abelmoschus esculentus Phytochemicals: Enzyme Inhibition, Molecular Docking, and Dynamics Simulation Against Key Antidiabetic Targets. (PubMed, Life (Basel)) - "The extract showed moderate-to-weak activity relative to standard inhibitors acarbose, sitagliptin, and orlistat. Free-energy landscape analysis revealed a well-defined single energy basin for alpha-Carotene, suggesting a thermodynamically stable binding conformation. These findings lay the molecular basis for using okra phytochemicals as adjunctive agents in diabetes management, though in vivo validation remains necessary."

Journal • Diabetes • Metabolic Disorders

Glucagon-Like Peptide-1 Receptor Agonists and Heart Failure Hospitalization in a Real-World Cardiometabolic Population. (PubMed, Am J Cardiol) - "Associations were also observed for lower rates of clinically diagnosed HFpEF (risk ratio 0.72; 95% confidence interval 0.70-0.74) and all-cause mortality. In conclusion, among adults with cardiometabolic risk and no prior heart failure, initiation of GLP-1 receptor agonist therapy was associated with lower rates of heart failure hospitalization compared with sitagliptin, suggesting potential modification of clinical trajectories leading to overt heart failure that warrants confirmation in prospective studies."

Journal • Real-world evidence • Cardiovascular • Congestive Heart Failure • Genetic Disorders • Heart Failure • Metabolic Disorders • Obesity

Efficacy and Safety of Fixed-Dose Combinations of Sitagliptin and Empagliflozin as Add-On to Metformin in Korean Patients With Type 2 Diabetes: A Randomised, Double-Blind, Multi-Centre, Placebo-Controlled, Phase III Trial. (PubMed, Diabetes Obes Metab) - P3 | "Sitagliptin/empagliflozin FDC doses achieved improvements in glycaemic control at 24 weeks, which was maintained through 52 weeks. These benefits were accompanied by a favourable safety profile, including a very low risk of hypoglycaemia."

Journal • P3 data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis. (PubMed, Andrology) - "This FDA Adverse Event Reporting System-based pharmacovigilance analysis identified potential safety signals linking erectile dysfunction to semaglutide, sitagliptin, and dapagliflozin. These findings do not establish causality and should be regarded as preliminary and hypothesis-generating. Further mechanistic and prospective clinical studies are needed to determine whether these signals reflect true drug-related risks. Clinicians should be aware that erectile dysfunction has been reported in some users of these agents and may consider incorporating sexual health into routine discussions and shared decision-making with male patients."

Journal • Diabetes • Erectile Dysfunction • Metabolic Disorders • Sexual Disorders

RECURRENT PARALYTIC ILEUS ASSOCIATED WITH TIRZEPATIDE ADMINISTRATION IN A 72-YEAR-OLD MALE AFTER ROBOT-ASSISTED RADICAL CYSTECTOMY WITH ILEAL CONDUIT CONSTRUCTION (ISN-WCN 2026) - "Two and a half years earlier, he was diagnosed with low-grade papillary urothelial carcinoma with early invasion and underwent five transurethral resections of bladder tumor (TUR-Bt) over 1.5 years.His medications included rosuvastatin, hydrochlorothiazide, eplerenone 50 mg, telmisartan 80 mg, amlodipine 5 mg, and glucose-lowering agents: dapagliflozin 10 mg, glimepiride, sitagliptin 50 mg, insulin glargine, and insulin human R. One week before surgery, insulin and oral glucose-lowering agents were replaced with tirzepatide 2.5 mg weekly...Chronic kidney disease alters drug pharmacokinetics and intestinal sensitivity [5], potentially amplifying GLP-1RA/GIP effects. These factors highlight the need for preventive measures against postoperative adhesions and electrolyte disturbances with acidosis."

Bladder Cancer • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Hypertension • Metabolic Disorders • Nephrology • Renal Disease • Solid Tumor • Type 2 Diabetes Mellitus • Urology • Urothelial Cancer

DPP-4 inhibitors for preventing post-stroke cognitive impairment in diabetic patients with acute ischemic stroke: a retrospective cohort study. (PubMed, Am J Transl Res) - "DPP-4i can lower PSCI risk in T2DM+AIS patients. Its mechanism involves multi-dimensional effects like anti-inflammation, anti-oxidation, insulin sensitivity enhancement, and neuroprotection."

Journal • Retrospective data • Alzheimer's Disease • Cardiovascular • Cognitive Disorders • Diabetes • Inflammation • Ischemic stroke • Metabolic Disorders • Type 2 Diabetes Mellitus • BDNF

Inclusion of GLP-1 and DPP-4 Inhibitor Sitagliptin in the Diabetes Mellitus Metabolic Simulator Research (DMMS.R) (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Diabetes • Metabolic Disorders

Neuroprotective effects of DPP-4 inhibitors sitagliptin and vildagliptin in Parkinson's disease via autophagy modulation. (PubMed, 3 Biotech) - "Together, these results position sitagliptin and vildagliptin as promising autophagy-modifying candidates for disease-modifying PD therapy. The online version contains supplementary material available at 10.1007/s13205-026-04761-8."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease • AKT1

Phase I/Ib study of inavolisib (INAVO) alone and in combination with endocrine therapy ± palbociclib (PALBO) in patients (pts) with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced/metastatic breast cancer (HR+, HER2– LA/mBC): Analysis of hyperglycemia (HG) in prediabetic/obese pts. (ASCO 2025) - P1 | "Clinical Trial Registration Number: NCT03006172 Background: INAVO, a highly potent and selective PI3Kα inhibitor that also promotes degradation of mutated p110α, is approved by the FDA in combination with PALBO + fulvestrant (FULV) for PIK3CA-mutated, HR+, HER2–, endocrine-resistant advanced BC... Adults ≥ 18 years of age received INAVO alone (Arm A), + letrozole (LET) + PALBO (Arm B), + LET (Arm C), + FULV (Arm D), + FULV + PALBO (Arm E), or + FULV + PALBO + primary prophylactic metformin (Arm F)...The most common anti-HG medications were metformin (52.7%; biguanide; concomitant use in Arm F excluded), empagliflozin (25.5%; SGLT-2 inhibitor), sitagliptin (22.7%; DPP-4 inhibitor), and pioglitazone (13.6%; thiazolidinedione); insulin was used in 8.2% of pts... A high proportion of prediabetic/obese pts were included in GO39374. In most of these pts, HG was manageable with dose interruptions and oral anti-HG medications, most commonly metformin. Data support the use..."

Clinical • Combination therapy • Metastases • P1 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Obesity • Oncology • Solid Tumor • HER-2 • PIK3CA

Potential gonadal-beneficial effect of sitagliptin against paclitaxel-induced testicular dysfunction via mediating PERK/CHOP/NLRP3/Sestrin2 signaling pathway. (PubMed, Sci Rep) - "SIT decreases cleaved caspase-3, caspase-3, and Cyt.c levels, verifying its anti-apoptotic features. Overall, SIT ameliorated PTX-provoked testicular dysfunction via mediating PERK/CHOP/NLRP3/Sestrin2 signaling pathway."

Journal • Oncology • CASP3 • CAT • IL1B • NLRP3

Acute Pancreatitis in a Young Patient With Type 2 Diabetes Mellitus Taking Sitagliptin and the Combined Oral Contraceptive Pill. (PubMed, Cureus) - "Sitagliptin was discontinued and replaced with gliclazide as opposed to metformin, which she was intolerant to. She demonstrated gradual improvement with normalization of inflammatory markers and triglyceride levels, achieving full recovery by day five. This case highlights the importance of considering sitagliptin and other medications, such as the combined oral contraceptive pill, as potential causes of acute pancreatitis and emphasizes the need for early recognition and prompt discontinuation of the offending agent to ensure optimal outcomes in patients."

Journal • Diabetes • Dyslipidemia • Gastroenterology • Hypertriglyceridemia • Inflammation • Metabolic Disorders • Pain • Pancreatitis • Severe Hypertriglyceridemia • Type 2 Diabetes Mellitus • CRP

Cinchona-Functionalized Crown-Ether-Pinioned Calix[4]arene for a Scalable Asymmetric Organocatalytic Aza-Michael Addition Reaction. (PubMed, Org Lett) - "The catalyst could be recycled up to 25 test cycles without any significant waning in the yield and selectivity. The synthetic application of this approach to DPP-4 inhibitor drugs, such as (R)-sitagliptin and evogliptin, further demonstrates its feasibility."

Journal

ARD-101, a gut-restricted TAS2R agonist, reduces hunger in adults and promotes weight loss in DIO mice with DPP-4 inhibition. (PubMed, Mol Metab) - P2 | "Gut-restricted TAS2R agonism warrants further study for hyperphagia in Prader-Willi syndrome, and in combination with DPP-4 inhibition for obesity."

Journal • Preclinical • Genetic Disorders • Obesity • Prader–Willi syndrome

Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Sex-, age-, and weight-related differences were noted for dulaglutide, liraglutide, semaglutide, sitagliptin, linagliptin, alogliptin, and saxagliptin. Median onset was shorter for GLP-1 RAs and tirzepatide (≤ 30 days) and longer for DPP-4is (55-132 days), with vildagliptin latest...Musculoskeletal AEs associated with incretin therapies differ by drug class and onset timing. Vigilant monitoring is needed during early GLP-1 RA or tirzepatide therapy and later during DPP-4i use to optimize patient safety."

Adverse events • Journal • Back Pain • Diabetes • Immunology • Metabolic Disorders • Muscular Atrophy • Musculoskeletal Diseases • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology • Type 2 Diabetes Mellitus

SITAGLIPTIN FOR PREVENTION OF ACUTE GVHD AFTER HAPLO-IDENTICAL PERIPHERAL BLOOD STEM CELL TRANSPLANTATION (EBMT 2026) - "In this study, patients who were pending to undergo PBSCT from an halo-identical donor were randomly allocated to high dose post-transplant cyclophosphamide, cyclosporine A and mycophenolate mofetil with (treatment arm) or without siglistatin (control arm) in a ratio of 2:1. The interim analysis of our clinical trial indicates that the addition of sitagliptin to the standard aGVHD prophylaxis regimen may reduce the incidence of aGVHD; the observed effect is clinically meaningful but attains only borderline statistical significance. These findings are constrained by the presently small sample size and short follow-up, therefore awaits continued patients enrollment and extended observation."

Acute Graft versus Host Disease • Graft versus Host Disease • Immunology • Infectious Disease • Septic Shock • Severe Hypoglycemia • Transplantation • CD34

SITAGLIPTIN FOR PREVENTION OF ACUTE GVHD AFTER HAPLO-IDENTICAL PERIPHERAL BLOOD STEM CELL TRANSPLANTATION (EBMT 2026) - "In this study, patients who were pending to undergo PBSCT from an halo-identical donor were randomly allocated to high dose post-transplant cyclophosphamide, cyclosporine A and mycophenolate mofetil with (treatment arm) or without siglistatin (control arm) in a ratio of 2:1. The interim analysis of our clinical trial indicates that the addition of sitagliptin to the standard aGVHD prophylaxis regimen may reduce the incidence of aGVHD; the observed effect is clinically meaningful but attains only borderline statistical significance. These findings are constrained by the presently small sample size and short follow-up, therefore awaits continued patients enrollment and extended observation."

Acute Graft versus Host Disease • Graft versus Host Disease • Immunology • Infectious Disease • Septic Shock • Severe Hypoglycemia • Transplantation • CD34

Assessing the therapeutic effects of DPP4 Inhibitors on TGF-β2-induced Lens Opacity. (PubMed, Exp Eye Res) - "In this study, we evaluated the potential efficacy of DPP4 inhibitors-specifically Sitagliptin, Saxagliptin, and Vildagliptin-in mitigating TGF-β-induced EMT in LECs. Notably, lens explant cultures treated with Vildagliptin showed a reduction in lens opacity induced by TGF-β2. These findings suggest that DPP4 inhibitors, particularly Vildagliptin, may offer a novel, non-invasive pharmacological approach to preventing PCO by targeting TGF-β signaling pathways."

Journal • Cataract • Fibrosis • Ophthalmology • FN1 • TGFB1 • VIM

A TRIAL EMULATION OF THE EFFECTS OF SITAGLIPTIN ON CARDIOVASCULAR OUTCOMES IN PEOPLE WITH TYPE 2 DIABETES USING UK CLINICAL PRACTICE RESEARCH DATALINK (CPRD) DATA (ATTD 2026) - "Sitagliptin treatment was not associated with an increased MACE risk in people with type 2 diabetes in the general population, in line with the TECOS trial."

Clinical • Cardiovascular • Diabetes • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus

REMISSION INDUCTION IN 138000 PATIENTS WITH TYPE II DIABETES (ATTD 2026) - "General treatment consisted of Sitagliptin, Empagliflozin 12.5 mg, Metformin 500mg, long acting Glyclazid 60mg, Valsartan 80mg (to activate Glut-4). This is the first systematic study on type II diabetes with the goal of complete remission and probably cure. Although the results are not uniform, 56% are in maintained complete remission for 6-72 months."

Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes (clinicaltrials.gov) - P4 | N=110 | Enrolling by invitation | Sponsor: Bahria University

New P4 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Dapa-LiT: Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation (clinicaltrials.gov) - P=N/A | N=100 | Completed | Sponsor: Medanta, The Medicity, India | Recruiting ➔ Completed | Trial completion date: Nov 2025 ➔ Feb 2026

Trial completion • Trial completion date • Diabetes • Metabolic Disorders • Transplantation

Efficacy of sitagliptin on blood pressure in patients with type 2 diabetes mellitus: a meta-analysis of randomized clinical trials. (PubMed, Eur J Med Res) - "Administration of sitagliptin was associated with a reduction of BP in patients with T2DM. However, its clinical role remained primarily glycemic control. The potential reduction of BP might be considered an ancillary benefit rather than a substitute for standard antihypertensive therapy. International prospective register for systematic review (PROSPERO) number: CRD42026128657."

Clinical • Journal • Retrospective data • Review • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Green MW/US route from lignocellulose to FDCA-based thiadiazol scaffolds: DPP-4/COX-1 inhibition and antioxidant evaluation. (PubMed, Bioorg Chem) - "Both compounds (4)) and (6) inhibited DPP-4 (IC50 = 0.304 ± 0.012 μg/mL; sitagliptin: 0.068 ± 0.003 μg/mL), and COX-1 (IC50 = 6.77 ± 0.25 μg/mL; ibuprofen: 2.18 ± 0.08 μg/mL). Compound (6) showed DPPH scavenging activity (IC50 = 34.54 ± 1.40 μg/mL; quercetin: 12.11 ± 0.49 μg/mL). The overall kinetic trends predicted experimentally were confirmed using docking studies and molecular dynamic analyses, both of which provided additional support for the presence of electronegative, stabilizing hydrogen bonds and electrostatic interactions at the designated target sites."

Journal